BCM
ELVN icon

Bridgeway Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Bridgeway Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,950
Closed -$245K – 1376
2023
Q3 		$245K Hold
17,950
– – 0.01% 1052
2023
Q2 		$366K Hold
17,950
– – 0.01% 996
2023
Q1 		$393K Sell
17,950
-6,975
-28% -$142K 0.01% 942
2022
Q4 		$408K Sell
24,925
-6,700
-21% -$107K 0.01% 931
2022
Q3 		$288K Hold
31,625
– – 0.01% 1053
2022
Q2 		$154K Sell
31,625
-3,875
-11% -$19K ﹤0.01% 1145
2022
Q1 		$267K Buy
35,500
+4,200
+13% +$27.7K 0.01% 1110
2021
Q4 		$282K Hold
31,300
– – 0.01% 1111
2021
Q3 		$511K Buy
+31,300
New +$650K 0.01% 1024

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridgeway Capital Management's ELVN Position: Q4 2023 in Review

Bridgeway Capital Management sold out of Enliven Therapeutics (ELVN) in Q4 2023, closing a stake of 17,950 shares — an estimated $245K sold.

Bridgeway Capital Management first reported a position in ELVN in Q3 2021 and held it in 9 quarters. The position peaked at $511K in Q3 2021. 62 funds tracked by Wall St. Rank hold ELVN as of Q4 2023.

  • Bridgeway Capital Management reported no remaining Enliven Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 17,950 Enliven Therapeutics shares in Q4 2023, an estimated $245K.
  • Bridgeway Capital Management first reported a position in Enliven Therapeutics in Q3 2021 and held it in 9 quarters.
  • Bridgeway Capital Management's Enliven Therapeutics position peaked at $511K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2023.

Based on Bridgeway Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.